Melanie Lawrence, an adult with cystic fibrosis, was selected to testify before a Senate Health, Education, Labor and Pensions subcommittee regarding the impact of antimicrobial resistance on patients who face heightened risk of infections, like those with CF.
Site Search
Showing 11 - 15 of 15 results
News
|
July 12, 2023
|
3 min read
The investment will go toward finishing a Phase 2a clinical trial for an anti-infective to treat chronic infections in people with CF.
News
|
Dec. 12, 2022
|
2 min read
Bill will jump-start rebuilding of the antibiotics pipeline that is vital to stave off a looming pandemic.
News
|
Nov. 16, 2022
|
3 min read
The Cystic Fibrosis Foundation has awarded up to $5.6 million to Microbion Corporation to develop a novel, inhaled antibiotic to treat drug-resistant bacterial infections in people with cystic fibrosis.
News
|
May 28, 2020
|
2 min read
The U.S. Food and Drug Administration (FDA) has approved TOBI® Podhaler™ (tobramycin inhalation powder), a dry powder formulation of the antibiotic TOBI, to treat lung infections caused by the bacteria Pseudomonas aeruginosa (P. aeruginosa).
News
|
March 25, 2013
|
1 min read